Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis

Journal of Thoracic Oncology

Volumn 2, Issue 1, 2007, Pages 51-58

  Buchholz, Erika ^a   Manegold, Christian ^a   Pilz, Lothar ^b   Thatcher, Nick ^c   Drings, Peter ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d Thoraxklinik Heidelberg ^*  (Germany)

Author keywords

Chemotherapy; Filgrastim; Hematopoietic progenitor cells; ICE; Small cell lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER PATIENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHY; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; DISEASE COURSE; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; SMALL CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; ERYTHROCYTE TRANSFUSION; ETOPOSIDE; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; PROGNOSIS; SURVIVAL RATE;

EID: 34249652554     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31802baf9d     Document Type: Article

References (43)

1. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-291.
2. Wolff AC, Ettinger DS, Neuberg D, et al. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1995;13:1615-1622.
3. Johnson BE, Ihde DC, Bunn PA, et al. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med 1985;103:430-438.
4. Thatcher N, Lind M, Stout R, et al. Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus. Br J Cancer 1989;60:98-101.
5. Shevlin PM, Muers MF, Peake MD, et al. Modified ice study: a phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with better prognosis, small cell lung cancer. Lung Cancer 1998;21:115-126.
6. Lorigan P, Lee SM, Betticher D, et al. Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer. Semin Oncol 1995;22:32-41.
7. Glisson B, Scott C, Komaki R, et al. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12. J Clin Oncol 2000;18:2990-2995.
8. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with oncedaily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271.
9. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-3060.
10. Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1993;11:1230-1240.
11. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-2034.
12. Spiro SG, Souhami RL, Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989;59:578-583.
13. Cerny T, Lind M, Thatcher N, et al. A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC). Br J Cancer 1989;60:258-261.
14. Pettengell R, Woll PJ, Thatcher N, et al. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995;13:148-156.
15. Buyse M, Staquet M, Sylvester Ret al. Cancer Clinical Trials Methods and Practice. Oxford, UK: Oxford University Press, 2005.
16. NCI-CTC. National Cancer Institute Cancer Therapy Evaluation Program Common Toxicity Criteria, version 2.0. Available at: http://ctep. cancer.gov/reporting/ctc.html. Accessed 1997.
17. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assos 1958;53:457-481.
18. Ardizzoni A, Tjan-Heijnen VC, Postmus PE, et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol 2002;20:3947-3955.
19. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848-1852.
20. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288.
21. Sheehan RG, Balaban EP, Frenkel EP. The impact of dose intensity of standard chemotherapy regimens in extensive stage small cell lung cancer. Am J Clin Oncol 1993;16:250-255.
22. Tjan-Heijnen VC, Wagener DJ, Postmus PE. An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol 2002;13:1519-1530.
23. Pasini F, Durante E, De Manzoni D, et al. High-dose chemotherapy in small-cell lung cancer. Anticancer Res 2002;22:3465-3472.
24. Evans WK, Stewart D, Logan D, et al. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer. Semin Oncol 1992;19:51-56.
25. Hand S, Baker J, Smith AP, et al. Outpatient intensive chemotherapy for small cell lung cancer: five years experience of modified 'ICE' ifosfamide carboplatin and etoposide. Clin Oncol (R Coll Radiol) 2002;14:367-371.
26. Prendiville J, Radford J, Thatcher N, et al. Intensive therapy for smallcell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. J Clin Oncol 1991;9:1446-1452.
27. Thatcher N, Lorrigan P, Burt P, et al. Intensive combined-modality therapy in small cell lung cancer. Semin Oncol 1994;21:9-22.
28. Pettengell R, Luft T, Henschler R, et al. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 1994;84:3653-3659.
29. Pettengell R, Woll PJ, O'Connor DA, Dexter TM, Testa NG. Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time. Bone Marrow Transplant 1994;14:703-709.
30. Rizzo JD, Elias AD, Stiff PJ, et al. Autologous stem cell transplantation for small cell lung cancer. Biol Blood Marrow Transplant 2002;8:273-280.
31. Souhami RL, Hajichristou HT, Miles DW, et al. Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. Cancer Chemother Pharmacol 1989;24:321-325.
32. Bessho A, Ueoka H, Kiura K, et al. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer. Anticancer Res 1999;19:693-698.
33. Calderoni A, von Briel C, Aebi S, et al. Intensive chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small cell lung cancer: a phase I/II trial. Lung Cancer 2002;36:321-326.
34. Elias AD, Ayash LJ, Wheeler C, et al. High-dose ifosfamide/carboplatin/ etoposide with autologous hematopoietic stem cell support: safety and future directions. Semin Oncol 1994;21:83-85.
35. Elias AD, Skarin AT, Richardson P, et al. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Biol Blood Marrow Transplant 2002;8:326-333.
36. Leyvraz S, Perey L, Rosti G, et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999;17:3531-3539.
37. Oelmann E, Thomas M, Serve H, et al. Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with stem cell rescue for smallcell lung cancer: brief report on the results of a phase-I/II trial. Oncology 2002;63:248-253.
38. Perey L, Rosti G, Lange A, et al. Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study. Bone Marrow Transplant 1996;18(suppl 1):S40-S43.
39. Woll PJ, Thatcher N, Lomax L, et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 2001;19:712-719.
40. Takahashi M, Yoshizawa H, Tanaka H, et al. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer. Bone Marrow Transplant 2000;25:5-11.
41. Woll PJ, Hodgetts J, Lomax L, et al. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995;13:652-659.
42. Lorigan P, Woll PJ, O'Brien MER, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005;97:666-674.
43. Steward WP, Von Pawel J, Gatzemeier U, et al. Effects of granulocytemacrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998;16:642-650.